Ligand Pharmaceuticals Relocates Executive Offices

TL;DR

Ligand Pharmaceuticals moved its HQ from CA to FL effective April 17th.

AI Summary

Ligand Pharmaceuticals Inc. filed an 8-K on April 19, 2024, reporting a change in its principal executive offices from San Diego, California to Jupiter, Florida, effective April 17, 2024. The new address is 555 Heritage Drive, Suite 200, Jupiter, Florida 33458. The company's phone number remains the same.

Why It Matters

This relocation of principal executive offices could indicate strategic shifts or operational changes within Ligand Pharmaceuticals, potentially impacting its operational footprint and proximity to key stakeholders or resources.

Risk Assessment

Risk Level: low — The filing solely reports a change of address for executive offices, which is a routine administrative event with no immediate financial or operational risk implied.

Key Players & Entities

• Ligand Pharmaceuticals Inc. (company) — Registrant
• 555 Heritage Drive, Suite 200, Jupiter, Florida 33458 (location) — New principal executive offices
• 3911 Sorrento Valley Blvd, Suite 110, San Diego, CA 92121 (location) — Former principal executive offices
• April 17, 2024 (date) — Effective date of change
• April 19, 2024 (date) — Filing date

FAQ

Key Financial Figures

• $0.001 — ich registered Common Stock, par value $0.001 per share LGND The Nasdaq Global Market

Filing Documents

• lgnd-20240417.htm (8-K) — 29KB
• exhibit31fifthamendedandre.htm (EX-3.1) — 159KB
• 0000886163-24-000013.txt ( ) — 347KB
• lgnd-20240417.xsd (EX-101.SCH) — 2KB
• lgnd-20240417_lab.xml (EX-101.LAB) — 22KB
• lgnd-20240417_pre.xml (EX-101.PRE) — 13KB
• lgnd-20240417_htm.xml (XML) — 3KB

03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year

Item 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year. On April 17, 2024, the Board of Directors (the "Board") of Ligand Pharmaceuticals Incorporated (the "Company"), in connection with the Securities and Exchange Commission's revisions to the Securities Exchange Act of 1934, as amended (the "Exchange Act") regarding universal proxy cards, changes to the Delaware General Corporation Law (the "DGCL"), and a periodic review of corporate governance matters, approved the amendment and restatement of the Company's Fourth Amended and Restated Bylaws, as amended (the "Fifth Amended and Restated Bylaws"). The Fifth Amended and Restated Bylaws, among other things: Make minor revisions to the informational and procedural requirements in connection with stockholder proposals and stockholder director nominations. (Article 2, Section 3 and Section 4); Make updates to account for Rule 14a-19 of the Exchange Act (the "Universal Proxy Rules"), including requiring: (a) the stockholder's nomination notice to include a representation that it intends to solicit proxies from stockholders representing at least 67% of the voting power of shares entitled to vote on the election of directors; (b) the stockholder to comply with the Universal Proxy Rules and provide reasonable evidence thereof prior to the stockholder meeting; and (c) the stockholder to use a proxy card color other than white, which is reserved for the exclusive use of the Board. (Article 2, Section 4 and Section 11); Clarify the requirement of the availability of lists of stockholders entitled to vote at stockholder meetings to reflect amendments to the DGCL. (Article 2, Section 6); Clarify that broker non-votes will have no effect on the outcome of a vote on a proxy proposal and abstentions will be counted as votes against (Article 2, Section 11); Make revisions regarding electronic notices to reflect amendments to the DGCL. (Article IV, Section 1); and Make various other conforming, tec

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 3.1 Fifth Amended and Restated Bylaws of Ligand Pharmaceuticals Incorporated dated April 17, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. LIGAND PHARMACEUTICALS INCORPORATED Date: April 19, 2024 By: /s/ Andrew Reardon Name: Andrew Reardon Title: Chief Legal Officer and Secretary

View Full Filing

View this 8-K filing on SEC EDGAR